Feds almost ready to charge drugmakers and executives in generics price-fixing probe

U.S. prosecutors have been digging into potential price-fixing in the generics world, and along the way, they've searched corporate offices and tracked executive movements at industry conferences. Now they're close to slapping charges on two companies and several execs, Bloomberg reports. The charges could come this summer, according to Bloomberg's sources, but those sources didn't disclose which companies or executives would be targeted. One revelation from the reporting? The feds raided Mylan's headquarters in September 2016 when CEO Heather Bresch was testifying to Congress about EpiPen price hikes, a source told Bloomberg. Mylan didn't immediately respond to a request for comment. The federal generic price-fixing investigation is separate from Mylan's EpiPen pricing controversy, which started in 2016 and continued into 2017.